Clinical Trial Update: Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib for squamous cell carcinoma of the bronchus after failure of first-line chemotherapy; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Bronchus
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Seoul Veterans Hospital | Conditions: Squamous Cell Carcinoma of Bronchus | Phase 2 | Status: COMPLETED